In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: A double-masked randomized study

Osteoporosis International

Volumn 6, Issue 2, 1996, Pages 171-177

  Guaydier Souquieres G ^a,e   Kotzki, P O ^b   Sabatier, J P ^a   Basse Cathalinat, B ^c   Loeb, G ^d  

^a CHU CÔTE DE NACRE   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c HÔPITAL PELLEGRIN   (France)

^d Yamanouchi Pharma ^*  (France)

^e CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Bone mineral density; Calcium; Corticosteroid; Double masked procedure; Monofluorophosphate; Osteopenia

Indexed keywords

CALCIUM; CORTICOSTEROID; FLUOCALCIC; FLUOROPHOSPHATE; PREDNISONE;

ADULT; ARTICLE; ASTHMA; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LEG PAIN; LUMBAR SPINE; MALE; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PHOTON ABSORPTIOMETRY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; STEROID THERAPY;

ABSORPTIOMETRY, PHOTON; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; BONE DENSITY; BONE DISEASES, METABOLIC; CALCIUM; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUORIDES; HUMANS; INCIDENCE; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; PHOSPHATES; PREDNISONE; PROSPECTIVE STUDIES; RESPIRATORY TRACT DISEASES; SPINAL FRACTURES;

EID: 0029874225     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01623943     Document Type: Article

References (35)

1. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983;309:265-8.
2. Meunier PJ. Is steroid-induced osteoporosis preventable? N Engl J Med 1993;328:1781-2.
3. Meunier PJ, Dempster DW, Edouard C, Chapuy MC, Arlot M, Charhon S. Bone histomorphometry in corticosteroid-induced osteoporosis and Cushing's syndrome. Adv Exp Med Biol 1984;171:191-200.
4. Dempster DW. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 1989;4:137-41.
5. Lukert BP, Raisz LG Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64.
6. Reid IR, Chapman GE, Fraser TRC, et al. Low serum osteocalcin levels in glucocorticoid-treated asthmatics. J Clin Endocrinol Metab 1986;62:379-83.
7. Kotowicz MA, Hall S, Hunder GG, Cedel SL, Mann KG, Riggs BL. Relationship of glucocorticoid dosage to serum bone Gla-protein concentration in patients with rheumatologic disorders. Arthritis Rheum 1990;33:1487-92.
8. Heaney RP, Baylink DJ, Johnston CC, et al. Fluoride therapy for the vertebral crush fracture syndrome. Ann Intern Med 1989;111:678-80.
9. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802-9.
10. Mamelle N, Meunier PJ, Dusan R, et al. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988;2:361-5.
11. Bayley TA, Muller C, Harrison J, et al. The long term treatment of steroid osteoporosis with fluoride. J Bone Miner Res 1990;5(Suppl 1):S157-61.
12. Meunier PJ, Briançon D, Chavassieux P, et al. Treatment with fluoride: bone histomorphometric findings. In: Christiansen C, Johansen JS, Riis BJ, editors. Osteoporosis 1987, vol 2. Copenhagen: Osteopress, 1987:824-8.
13. Greenwald M, Brandli D, Spector S, Silverman S, Golde G. Corticosteroid-induced osteoporosis: effects of a treatment with slow-release sodium fluoride. Osteoporosis Int 1992;2:303-4.
14. Meys E, Terreaux-Duvert F, Beaume-Six T, Dureau G, Meunier PJ. Bone loss after cardiac transplantation: effects of calcium, calcidiol and monofluorophosphate. Osteoporosis Int 1993; 3:322-9.
15. Delmas PD, Dupuis J, Duboeuf F, Chapuy MC, Meunier PJ. Treatment of vertebral osteoporosis with disodium monofluorophosphate: comparison with sodium fluoride. J Bone Miner Res 1990;5(Suppl 1):S143-7.
16. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report no. 843. Geneva: World Health Organization, 1994:1-129.
17. Sambrook P, Birmingham J, Kempler S, et al. Corticosteroid effects on proximal femur bone loss. J Bone Miner Res 1990;5:1211-6.
18. LoCascio V, Bonucci E, Imbibo B, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990;8:39-51.
19. Johnston CC, Melton LJ, Lindsay R, Eddy DM. Clinical indications for bone mass measurements. Report from the Scientific Advisory Board of the National Osteoporosis Foundation. J Bone Miner Res 1989; 4(Suppl 2):S1-28.
20. Groupe de Recherche et d'Information sur les Ostéoporoses (GRIO). Intérêt et indications cliniques des mesures de masse osseuse par absorptiométrie biphotonique à rayons X. Rapport du Comité Scientifique du GRIO. Rev Rhum [Ed Fr] 1994;61 (Suppl 7-8 bis): S69-86.
21. Rizzoli R, Chevalley T, Slosman DO, Bonjour JP. Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis. Osteoporosis Int 1995;5:39-46.
22. Pouilles JM, Tremollières F, Causse E, Louvet JP, Ribot C. Fluoride therapy in postmenopausal osteopenic women: effect on vertebral and femoral bone density and prediction of bone response. Osteoporosis Int 1991;1:103-9.
23. Sebert JL, Richard P, Mennecier I, Bisset JP, Loeb G. Monofluorophosphate increases lumbar bone density in osteopenic patients: a double-masked randomized study. Osteoporosis Int 1995;5:108-14.
24. Hansson T, Roos B. The effect of fluoride and calcium on spinal bone mineral content: a controlled, prospective (3 years) study. Calcif Tissue Int 1987;40:315-7.
25. Nagant de Deuxchaisnes C, Devogelaer JP, Depresseux G, Malghem J, Maldague B. Treatment of the vertebral crush fracture syndrome with enteric-coated sodium fluoride tablets and calcium supplements. J Bone Miner Res 1990;5(Suppl 1):S5-26.
26. Raymakers JA, Van Dijke CF, Hoekstra A, Duursma SA. Monitoring fluoride therapy in osteoporosis by dual photon absorptiometry. Bone 1987;8:143-8.
27. Reid IR, Ibbertson HK. Calcium supplements in the prevention of steroid-induced osteoporosis. Am J Clin Nutr 1986;44:287-90.
28. Meunier PJ, Boivin G. Fluoride salts for vertebral osteoporosis: the benefit to risk ratio depends on the cumulative dose reaching bone. Osteoporosis Int 1993;3(Suppl 1):S211-4.
29. Lundy MW, Stauffer M, Wergedal JE, et al. Histomorphometric analysis of iliac crest bone biopsies in placebo-treated versus fluoride-treated subjects. Osteoporosis Int 1995;5:115-29.
30. Kleerekoper M, Peterson EL, Nelson DA, et al. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis Int 1991;1:155-61.
31. - per day) does not increase lumbar bone mineral density in postmenopausal osteopenia: a double-blind randomized study [abstract 225]. The XXIVth European Symposium on Calcified Tissues, Aarhus, May 27-30 1995. Calcif Tissue Int 1995;56:479.
32. Farley SM, Wergedal JE, Farley JR, et al. Spinal fractures during fluoride therapy for osteoporosis: relationship to spinal bone density. Osteoporosis Int 1992;2:213-8.
33. Riggs B, O'Fallon W, Hodgson S, et al. Clinical trial of fluoride in osteoporotic women: extended observation and additional analyses. In: Conn DV, editor. Program and Abstracts, XIth International Conference on Calcium Regulating Hormones, Florence, 1992. Bone Miner 1992;17(Suppl 1):74.
34. Reginster JY. Treatment of postmenopausal osteoporosis with sodium monofluorophosphate: preliminary results of a long-term double-blind placebo-controlled study. In: Christiansen C, Riis B, editors. Proceedings of the Fourth International Symposium on Osteoporosis, Hong Kong, 1993:435-7.
35. Ringe JD, Meunier PJ. What is the future for fluoride in the treatment of osteoporosis? Osteoporosis Int 1995;5:71-4.